- Home
- PAYO vs IMVT Comparison
PAYO vs IMVT Comparison
Compare PAYO & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYO
- IMVT
- Stock Information
- Founded
- PAYO 2005
- IMVT N/A
- Country
- PAYO United States
- IMVT United States
- Employees
- PAYO N/A
- IMVT N/A
- Industry
- PAYO EDP Services
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAYO Technology
- IMVT Health Care
- Exchange
- PAYO Nasdaq
- IMVT Nasdaq
- Market Cap
- PAYO 2.2B
- IMVT 2.5B
- IPO Year
- PAYO N/A
- IMVT N/A
- Fundamental
- Price
- PAYO $6.78
- IMVT $15.41
- Analyst Decision
- PAYO Strong Buy
- IMVT Buy
- Analyst Count
- PAYO 8
- IMVT 10
- Target Price
- PAYO $10.44
- IMVT $40.14
- AVG Volume (30 Days)
- PAYO 4.3M
- IMVT 1.1M
- Earning Date
- PAYO 05-07-2025
- IMVT 05-29-2025
- Dividend Yield
- PAYO N/A
- IMVT N/A
- EPS Growth
- PAYO N/A
- IMVT N/A
- EPS
- PAYO 0.28
- IMVT N/A
- Revenue
- PAYO $996,150,000.00
- IMVT N/A
- Revenue This Year
- PAYO $4.12
- IMVT $108.88
- Revenue Next Year
- PAYO $4.91
- IMVT N/A
- P/E Ratio
- PAYO $24.18
- IMVT N/A
- Revenue Growth
- PAYO 14.86
- IMVT N/A
- 52 Week Low
- PAYO $5.03
- IMVT $12.72
- 52 Week High
- PAYO $11.29
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- PAYO 45.81
- IMVT 55.46
- Support Level
- PAYO $6.77
- IMVT $13.79
- Resistance Level
- PAYO $6.94
- IMVT $15.22
- Average True Range (ATR)
- PAYO 0.19
- IMVT 0.70
- MACD
- PAYO -0.02
- IMVT 0.17
- Stochastic Oscillator
- PAYO 12.37
- IMVT 96.18
About PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).